Literature DB >> 17174192

Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations.

Tjeerd Germans1, Arthur A M Wilde, Pieter A Dijkmans, Wenxia Chai, Otto Kamp, Yigal M Pinto, Albert C van Rossum.   

Abstract

OBJECTIVES: The purpose of this study was to evaluate whether structural left ventricular (LV) abnormalities can be observed in hypertrophic cardiomyopathy (HCM) mutation carriers who have not yet developed echocardiographic signs of hypertrophy by using cardiac magnetic resonance imaging (CMR).
BACKGROUND: Hypertrophic cardiomyopathy is caused by mutations of genes encoding for sarcomeric proteins. Myocyte disarray and interstitial fibrosis precede the development of regional hypertrophy in HCM mutation carriers (carriers). No macroscopic LV structural abnormalities have been observed in carriers without LV hypertrophy.
METHODS: A CMR, echocardiogram, and electrocardiogram (ECG) were performed in 16 carriers. Delayed contrast enhancement imaging was used with CMR to detect fibrosis. In 16 age- and gender-matched control subjects, CMR and ECG were performed and an echocardiogram was made when structural abnormalities were detected with CMR. All carriers had an LV wall thickness <13 mm in the year before the study, measured by echocardiography.
RESULTS: In 13 carriers (81%), crypts were discerned with CMR in the basal and mid inferoseptal LV wall, not detected by routine echocardiography and not observed in healthy volunteers. In 4 of the crypt-positive carriers, both the echocardiogram and ECG were normal. Two HCM carriers revealed regional hypertrophy of the inferoseptum not detected by echocardiography, and in both carriers, focal fibrosis was present.
CONCLUSIONS: In carriers who have not yet developed frank hypertrophy, crypts can be detected with CMR in the inferoseptal LV wall, even when echocardiography and ECG are normal. The crypts might represent one of the early pathological alterations of myocardium in carriers that ultimately progress into manifest HCM.

Entities:  

Mesh:

Year:  2006        PMID: 17174192     DOI: 10.1016/j.jacc.2006.08.036

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  56 in total

1.  Evaluation of hypertrophic cardiomyopathy: new horizons for CMR?

Authors:  E E van der Wall; H M Siebelink; J J Bax
Journal:  Neth Heart J       Date:  2010-03       Impact factor: 2.380

2.  Structural abnormalities of the left ventricle in hypertrophic cardiomyopathy mutation carriers detectable before the development of hypertrophy.

Authors:  T Germans; A A M Wilde; C J A van Echteld; O Kamp; Y M Pinto; A C van Rossum
Journal:  Neth Heart J       Date:  2007       Impact factor: 2.380

Review 3.  Contemporary treatment of hypertrophic cardiomyopathy.

Authors:  Ali J Marian
Journal:  Tex Heart Inst J       Date:  2009

4.  Could two-dimensional radial strain be considered as a novel tool to identify pre-clinical hypertrophic cardiomyopathy mutation carriers?

Authors:  Gloria Maria Santambrogio; Alessandro Maloberti; Paola Vallerio; Angelica Peritore; Francesca Spanò; Lucia Occhi; Francesco Musca; Oriana Belli; Benedetta De Chiara; Francesca Casadei; Rita Facchetti; Fabio Turazza; Emanuela Manfredini; Cristina Giannattasio; Antonella Moreo
Journal:  Int J Cardiovasc Imaging       Date:  2019-07-18       Impact factor: 2.357

5.  Prevalence and morphology of myocardial crypts in normal and hypertrophied myocardium by computed tomography.

Authors:  Ziad Arow; Mithal Nassar; Daniel Monakier; Abid Assali; Hana Vaknin-Assa; Ran Kornowski; Ashraf Hamdan
Journal:  Int J Cardiovasc Imaging       Date:  2019-03-05       Impact factor: 2.357

Review 6.  Research priorities in sarcomeric cardiomyopathies.

Authors:  Jolanda van der Velden; Carolyn Y Ho; Jil C Tardiff; Iacopo Olivotto; Bjorn C Knollmann; Lucie Carrier
Journal:  Cardiovasc Res       Date:  2015-01-28       Impact factor: 10.787

7.  Three-dimensional speckle tracking echocardiography for the preclinical diagnosis of hypertrophic cardiomyopathy.

Authors:  Mohamed F A Aly; Wessel P Brouwer; Sebastiaan A Kleijn; Albert C van Rossum; Otto Kamp
Journal:  Int J Cardiovasc Imaging       Date:  2014-01-30       Impact factor: 2.357

8.  Multiple left ventricular inferoseptal clefts. Multimodality imaging appearance and differential diagnosis.

Authors:  M Wein; A Wolf-Puetz; R Niehues; T Klein; P J Kilner; R M Klein
Journal:  Herz       Date:  2011-08       Impact factor: 1.443

9.  Hypertrophic cardiomyopathy family with double-heterozygous mutations; does disease severity suggest doubleheterozygosity?

Authors:  I A W van Rijsingen; J F Hermans-van Ast; Y H J M Arens; S M Schalla; C E M de Die-Smulders; A van den Wijngaard; Y M Pinto
Journal:  Neth Heart J       Date:  2009-12       Impact factor: 2.380

10.  How do hypertrophic cardiomyopathy mutations affect myocardial function in carriers with normal wall thickness? Assessment with cardiovascular magnetic resonance.

Authors:  Tjeerd Germans; Iris K Rüssel; Marco J W Götte; Marieke D Spreeuwenberg; Pieter A Doevendans; Yigal M Pinto; Rob J van der Geest; Jolanda van der Velden; Arthur A M Wilde; Albert C van Rossum
Journal:  J Cardiovasc Magn Reson       Date:  2010-03-15       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.